[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362863-105":59,"doc-detail-362863-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","liquid-biopsies-using-circulating-tumor-dna-for-surveillance-of-gastrointestinal-cancers-in-hispanics-first-real-world-data-report","Liquid biopsies using circulating tumor DNA for surveillance of gastrointestinal cancers in Hispanics - first real-world data report","","Liquid biopsies using circulating tumor DNA (ctDNA) provide tumor-specific mutation information and can support monitoring of disease burden and minimal residual disease (MRD). This retrospective real-world study evaluated adoption of ctDNA testing in a community oncology practice and assessed diagnostic performance and association with progression in 88 gastrointestinal cancer patients, predominantly stage IV colorectal cancer (CRC). In stage IV CRC, ctDNA rose before radiologic progression in all cases, with a median lead time of 2.5 months.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liquid-biopsies-using-circulating-tumor-dna-for-surveillance-of-gastrointestinal-cancers-in-hispanics-first-real-world-data-report/362863/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liquid-biopsies-using-circulating-tumor-dna-for-surveillance-of-gastrointestinal-cancers-in-hispanics-first-real-world-data-report/362863.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main objective?","Question",{"text":112,"@type":113},"To evaluate adoption of ctDNA testing in a community oncology practice and assess diagnostic performance and its relationship to disease progression in stage IV colorectal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients were included and which cancer types were most common?",{"text":117,"@type":113},"The study analyzed 88 patients with gastrointestinal cancers, with colorectal cancer accounting for 80 of 88 patients (90.1%).",{"name":119,"@type":110,"acceptedAnswer":120},"What did ctDNA show relative to radiologic progression in stage IV colorectal cancer?",{"text":121,"@type":113},"In stage IV CRC, ctDNA increased before radiologic progression in all documented cases (100%), with a median lead time of 2.5 months (range 0.5–15 months).",{"name":123,"@type":110,"acceptedAnswer":124},"How did ctDNA performance differ in early-stage colorectal cancer (I–III)?",{"text":125,"@type":113},"In early-stage CRC (I–III), ctDNA preceded radiologic progression in 40% of cases, with a median lead time of 6 months (range 6–10 months).","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},362863,1790759389,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","ORIGINAL ARTICLE  \nLiquid biopsies using circulating tumor DNA for surveillance of gastrointestinal cancers in Hispanics: first real-world data report  \nC. Cardona-De Jesús1†, H. Centeno-Girona2 , 3†, F. Garau-Rolón1, H. Melero-Rodríguez1, I. Alicea1 & M. Cruz-Correa1 , 2 , 3 ∗  \n1Dr. Isaac Gonzalez Martinez Oncology Hospital, San Juan; 2University of Puerto Rico Medical Sciences Campus, San Juan; 3University of Puerto Rico Comprehensive Cancer Center, San Juan, USA  \nAvailable online 14 January 2026  \nBackground: Malignant tumors release circulating tumor DNA (ctDNA) into the bloodstream, providing insights into tumor-specific mutations and pathways driving cancer progression. ctDNA testing is currently approved as a type of liquid biopsy to monitor disease burden and detect minimal residual disease (MRD) . This study aimed to evaluate the adoption of ctDNA testing in a community oncology practice and assess the overall diagnostic performance of ctDNA and its association with disease progression in stage IV colorectal cancer (CRC), as determined by imaging studies.  \nPatients and methods: This retrospective study analyzed the medical records of 88 patients with gastrointestinal cancers (80 CRC, 5 gastric, 3 esophageal) who underwent ctDNA molecular testing between January 2020 and April 2022. Electronic medical records from patients aged ≥21 years who had two or more ctDNA tests with concurrent imaging studies or a pathology-confirmed CRC, gastric cancer, or esophageal cancer diagnosis were evaluated. Results: At baseline, 47 (53 .4%) patients had negative and 41 (46 .6%) had positive results. Most patients had CRC (90 . 1%) . In stage IV CRC, ctDNA was increasing before radiologic progression in all documented cases (100%), with a median lead time of 2.5 months (range 0.5-15 months) . In early-stage CRC (I-III), ctDNA preceded radiologic progression in 40% of cases, with a median lead time of 6 months (range 6-10 months) .  \nConclusions: Using real-world data, we report the first-time results of the ctDNA testing adoption in a community oncology setting among patients with gastrointestinal cancers, predominantly CRC. Our findings suggest that integration of ctDNA testing may support disease monitoring in routine clinical practice.  \nKey words: liquid biopsy, molecular diagnostics, tumor surveillance, cancer monitoring, precision oncology, noninvasive biomarkers  \nINTRODUCTION  \nGastrointestinal cancers are responsible for a significant disease burden among United States Hispanics, particularly Puerto Rican Hispanics (PRH) .1,2 From 2016 to 2020, the age-adjusted incidences of colorectal cancer (CRC), gastric cancer, and esophageal cancer among PRH were 35.0, 5.8, and 2.5 per 100 000 population, respectively.2 Meanwhile, the age-adjusted mortality rates for these cancers were 12.5, 2. 2, and 1.8 per 100 000, respectively. In comparison, the overall United States population had incidences of 38 . 1, 6.5, and 2.8 per 100 000, with mortality rates of 13.9, 3.5,  \n*Correspondence to: Dr Marcia Cruz-Correa, PO BOX 365067, University of Puerto Rico, Medical Sciences Campus, San Juan, PR, 00936-5067, USA. Tel:+1-787-772-8300  \n[E-mail:](E-mail: marcia.cruzcorrea@upr.edu)[ marcia.cruzcorrea@upr.edu](E-mail: marcia.cruzcorrea@upr.edu) (M. Cruz-Correa).  \n†These authors contributed equally to this work.  \n2949-8201/© 2025 Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nand 2.0 per 100 000, respectively.2 Despite having similar incidence and mortality rates, PRH remain underrepresented in clinical studies, including those evaluating innovative surveillance methods.3-7 Furthermore, the genetic admixture of PRH can affect cancer susceptibility, progression, and response to treatment, highlighting the importance of research that addresses biolo","cbCaitqH45YzEbNY","https://ap.wps.com/l/cbCaitqH45YzEbNY","pdf",500290,"English","# Background\n# Patients and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To evaluate adoption of ctDNA testing in a community oncology practice and assess diagnostic performance and its relationship to disease progression in stage IV colorectal cancer.\"},{\"question\":\"How many patients were included and which cancer types were most common?\",\"answer\":\"The study analyzed 88 patients with gastrointestinal cancers, with colorectal cancer accounting for 80 of 88 patients (90.1%).\"},{\"question\":\"What did ctDNA show relative to radiologic progression in stage IV colorectal cancer?\",\"answer\":\"In stage IV CRC, ctDNA increased before radiologic progression in all documented cases (100%), with a median lead time of 2.5 months (range 0.5–15 months).\"},{\"question\":\"How did ctDNA performance differ in early-stage colorectal cancer (I–III)?\",\"answer\":\"In early-stage CRC (I–III), ctDNA preceded radiologic progression in 40% of cases, with a median lead time of 6 months (range 6–10 months).\"}]","Liquid biopsies using circulating tumor DNA for surveillance of gastrointestinal cancers in Hispanics - first real-world data report | PDF",1790149263,15,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3861c46ae2c741849d5ac106bc987cf3.webp",983,1269,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1cbc8d2de9d08daa63ca47aea277c64.webp",982,1268,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/031a9474b7723d054aa32e4367487000.webp",981,1266,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f89f3998b189e8ae0bf9bee4c4700b0e.webp",980,1265]